![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, January 31, 2023 1:08:12 PM
https://www.takeda.com/newsroom/newsreleases/2022/takedas-biologics-license-application-bla-for-dengue-vaccine-candidate-tak-003-granted-priority-review-by-us-food-and-drug-administration
4 months or less until an answer. Expedited review is six months or less now. It was accepted Nov 22nd.
Big if we get FDA apprvoval. ETF's in the know are sucking up shares.
Other approved drug has serious side effects vs. ours.
300M cases a year from mosquito bites.
Boing X 2
Recent TAK News
- Takeda kündigt neue Besetzung der Direktorenposten an • Business Wire • 06/26/2024 11:43:00 PM
- Takeda annonce de nouvelles nominations de directeurs • Business Wire • 06/26/2024 11:25:00 PM
- Takeda Announces New Assignments of Directors • Business Wire • 06/26/2024 07:05:00 AM
- 取締役分掌等の決定について • Business Wire • 06/26/2024 07:05:00 AM
- Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies • Business Wire • 06/24/2024 07:00:00 AM
- Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia • Business Wire • 06/23/2024 02:30:00 AM
- HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda • GlobeNewswire Inc. • 06/21/2024 08:00:00 PM
- Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer • Business Wire • 06/21/2024 08:00:00 PM
- HyQviaMD de Takeda approuvé comme traitement substitutif chez les enfants de 2 ans ou plus atteints d'immunodéficience humorale primaire ou secondaire • PR Newswire (Canada) • 06/21/2024 12:00:00 PM
- Takeda's HyQvia® Approved as Replacement Therapy for Primary Humoral Immunodeficiency and Secondary Humoral Immunodeficiency in Pediatric Patients 2 years of Age and Older • PR Newswire (Canada) • 06/21/2024 12:00:00 PM
- 武田薬品、PNS年次総会にて慢性炎症性脱髄性多発神経炎(CIDP)患者を対象としたHYQVIA®の第3相ADVANCE-CIDP3臨床試験の長期データを発表 • Business Wire • 06/20/2024 02:36:00 PM
- Takeda présente au congrès annuel de la PNS des données à long terme de l’essai clinique ADVANCE-CIDP 3 de Phase 3 portant sur l’administration de HYQVIA® à des patients atteints de polyradiculonévrite inflammatoire démyélinisante chronique (P • Business Wire • 06/19/2024 05:25:00 PM
- Takeda präsentiert Langzeitdaten der klinischen Phase-3-Studie ADVANCE-CIDP 3 mit HYQVIA® bei Patienten mit chronisch entzündlicher demyelinisierender Polyneuropathie (CIDP) auf der PNS-Jahrestagung • Business Wire • 06/19/2024 08:24:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/17/2024 10:46:29 AM
- Takeda Announces Phase 3 Topline Results for Soticlestat (TAK-935) in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome • Business Wire • 06/17/2024 10:45:00 AM
- Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI) • Business Wire • 06/14/2024 12:00:00 PM
- Takeda Announces Partnership Expansion with Partners In Health to Extend Community-Centered Health Equity Initiative Across Massachusetts • Business Wire • 06/11/2024 12:00:00 PM
- Takeda’s TAK-861 Phase 2b Late-Breaking Data Presentations at SLEEP 2024 Demonstrate Clinically Meaningful Impact of Oral Orexin Agonist in Narcolepsy Type 1 Compared to Placebo • Business Wire • 06/03/2024 10:45:00 AM
- Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma • Business Wire • 06/01/2024 12:00:00 PM
- Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 (rADAMTS13) in Congenital Thrombotic Thrombocytopenic Purpura (cTTP) • Business Wire • 05/31/2024 01:57:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/21/2024 10:02:25 AM
- Takeda Canada Inc. concludes Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for LIVTENCITY® (maribavir) for the treatment of adults with a post-transplant cytomegalovirus (CMV) infection • PR Newswire (Canada) • 05/16/2024 12:02:00 PM
- Takeda Canada Inc. conclut une lettre d'intention avec l'Alliance pancanadienne pharmaceutique (APP) concernant LIVTENCITY® (maribavir) pour le traitement des adultes greffés atteints d'une infection à cytomégalovirus (CMV) • PR Newswire (Canada) • 05/16/2024 12:02:00 PM
- Takeda to Present Oncology Portfolio and Pipeline Data at the 2024 ASCO Annual Meeting • Business Wire • 05/14/2024 12:00:00 PM
- Takeda annonce ses résultats pour l’exercice 2023 et ses perspectives pour l’exercice 2024, confirmant son engagement en faveur du développement d’un portefeuille de produits à un stade avancé et de l’augmentation de la marge bénéficiaire... • Business Wire • 05/10/2024 11:03:00 AM
FEATURED BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • Jul 2, 2024 7:19 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM